Clinical Remission of Chronic Spontaneous Urticaria (CSU): A Targeted Literature Review.

Chronic spontaneous urticaria Duration of disease Natural clinical remission Remission rate

Journal

Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 28 09 2021
pubmed: 23 11 2021
medline: 23 11 2021
entrez: 22 11 2021
Statut: ppublish

Résumé

Chronic spontaneous (previously known as idiopathic) urticaria (CSU) is a chronic skin disease with the potential for natural remission. The objectives of this targeted literature review were to identify evidence on the clinical course of CSU, including remission rates, and to estimate cumulative remission rates for different time points. Electronic databases (MEDLINE, MEDLINE-In Process, Embase, Web of Science, BIOSIS Previews and the Cochrane Library) and relevant conference proceedings were searched to identify studies involving patients with CSU aged ≥ 12 years that provide data on remission rates and disease duration. Observational studies with patient follow-ups of ≥ 1 year or review articles were included. Data extracted from five selected studies were used to run Kaplan-Meier (KM) analyses and best-fit distributions to calculate remission rates per 4-week period and weighted averages. Ten publications were included in this review. The proportion of patients achieving remission within year 1 ranged from 21 to 47%, while reported remission rate estimates at year 5 were 34% and 45%. Based on calculated 4-weekly remission rates, cumulative remission estimates ranged from 9 to 38% at year 1, from 29 to 71% at year 5 and from 52 to 93% at year 20. Cumulative weighted average estimates for the proportion of patients remitting at years 1, 5 and 20 were 17%, 45% and 73%, respectively. Published evidence suggests that CSU is a self-limiting condition with variable disease severity and duration, apparently dependent on multiple factors. However, data sources differed in terms of definitions of disease severity and remission, as well as in conclusions on influencing factors. Further studies and uniform definitions are required.

Identifiants

pubmed: 34807372
doi: 10.1007/s13555-021-00641-6
pii: 10.1007/s13555-021-00641-6
pmc: PMC8776966
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

15-27

Informations de copyright

© 2021. The Author(s).

Références

Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA
doi: 10.1111/all.12313
Staubach P, Eckhardt-Henn A, Dechene M, et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol. 2006;154(2):294–8.
doi: 10.1111/j.1365-2133.2005.06976.x
Maurer M, Abuzakouk M, Berard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005–16.
doi: 10.1111/all.13209
Zuberbier T, Asero R, Bindslev-Jensen C, et al. The International EAACI/GA
doi: 10.1111/all.15090 pubmed: 34932829
Maurer M, Magerl M, Metz M, Zuberbier T. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges. 2013;11(10):971–7.
pubmed: 24034140
Beltrani VS. An overview of chronic urticaria. Clin Rev Allergy Immunol. 2002;23:147–69.
doi: 10.1385/CRIAI:23:2:147
Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol. 2001;45(3):387–91.
doi: 10.1067/mjd.2001.116217
Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol. 2007;34(5):294–301.
doi: 10.1111/j.1346-8138.2007.00276.x
Nebiolo F, Bergia R, Bommarito L, et al. Effect of arterial hypertension on chronic urticaria duration. Ann Allergy Asthma Immunol. 2009;103(5):407–10.
doi: 10.1016/S1081-1206(10)60360-2
van der Valk PG, Moret G, Kiemeney LA. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol. 2002;146(1):110–3.
doi: 10.1046/j.1365-2133.2002.04582.x
Boonpiyathad T, Sangasapaviliya A. Autologous serum and plasma skin test to predict 2-year outcome in chronic spontaneous urticaria. Asia Pac Allergy. 2016;6(4):226–35.
doi: 10.5415/apallergy.2016.6.4.226
Chuamanochan M, Kulthanan K, Tuchinda P, Chularojanamontri L, Nuchkull P. Clinical features of chronic urticaria in aging population. Asian Pac J Allergy Immunol. 2016;34(3):201–5.
pubmed: 27001657
Kim YS, Park SH, Han K, et al. Clinical course of chronic spontaneous urticaria in the Korean adult population. Allergy Asthma Immunol Res. 2018;10(1):83–7.
doi: 10.4168/aair.2018.10.1.83
Toubi EKA, Avshovich N, Bamberger E, Sabo E. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy. 2004;59:869–73.
doi: 10.1111/j.1398-9995.2004.00473.x
Rabelo-Filardi R, Daltro-Oliveira R, Campos RA. Parameters associated with chronic spontaneous urticaria duration and severity: a systematic review. Int Arch Allergy Immunol. 2013;161(3):197–204.
doi: 10.1159/000346896

Auteurs

Maria-Magdalena Balp (MM)

Novartis Pharma AG, Basel, Switzerland.

Anna C Halliday (AC)

Health Economics and Outcomes Research, Novartis Pharmaceuticals UK Limited, London, UK.

Thomas Severin (T)

Novartis Pharma AG, Basel, Switzerland.

Saoirse A Leonard (SA)

Costello Medical Ltd, Cambridge, UK.

Gautam Partha (G)

Novartis Healthcare Pvt. Ltd., Hyderabad, India.

Manik Kalra (M)

Novartis Healthcare Pvt. Ltd., Hyderabad, India. manik.kalra@novartis.com.

Alexander M Marsland (AM)

Department of Dermatology & University of Manchester, Salford Royal Foundation Trust, Manchester, UK.

Classifications MeSH